Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines [Seeking Alpha]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » fuzznails/iStock via Getty Images Investment Overview The stock of Palo Alto, California based Kodiak Sciences Inc. ( KOD ) soared in value yesterday, reaching a high of $75 per share (market cap of $2.43bn), as the company announced positive results from its GLOW2 Phase 3 More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharm
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak Sciences (KOD) had its price target raised by UBS Group AG from $50.00 to $80.00. They now have a "buy" rating on the stock.MarketBeat
- Kodiak Sciences (KOD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock, up from $38.00.MarketBeat
- Kodiak Sciences (KOD) CLimbs 75% on Stellar Clinical Results [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over ShamPR Newswire
KOD
Earnings
- 11/13/25 - Miss
KOD
Sec Filings
- 3/27/26 - Form 4
- 3/27/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- KOD's page on the SEC website